9 results match your criteria: "Jules Gonin Ophthalmic Hospital[Affiliation]"
Binocular Diplopia: A Possible Adverse Effect of Fluoroquinolone Therapy.
Case Rep Ophthalmol Med
November 2020
Etablissements Hospitaliers du Nord Vaudois, Internal Medicine, Saint-Loup Hospital, Pompaples, Switzerland.
The adverse effects of fluoroquinolones are yet to be fully elucidated. We present an interesting case of a 41-year-old male with binocular diplopia most likely induced by the use of a fluoroquinolone antibiotic.
View Article and Find Full Text PDFMutations in CEP78 Cause Cone-Rod Dystrophy and Hearing Loss Associated with Primary-Cilia Defects.
Am J Hum Genet
September 2016
Department of Computational Biology, Unit of Medical Genetics, University of Lausanne, 1011 Lausanne, Switzerland. Electronic address:
Cone-rod degeneration (CRD) belongs to the disease spectrum of retinal degenerations, a group of hereditary disorders characterized by an extreme clinical and genetic heterogeneity. It mainly differentiates from other retinal dystrophies, and in particular from the more frequent disease retinitis pigmentosa, because cone photoreceptors degenerate at a higher rate than rod photoreceptors, causing severe deficiency of central vision. After exome analysis of a cohort of individuals with CRD, we identified biallelic mutations in the orphan gene CEP78 in three subjects from two families: one from Greece and another from Sweden.
View Article and Find Full Text PDFAnti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats.
Invest Ophthalmol Vis Sci
April 2016
Inserm UMR_S 1138, Team 17: From Physiopathology of Retinal Diseases to Clinical Advances, Centre de Recherche des Cordeliers, Paris, France 3Sorbonne Universities, University of Pierre et Marie Curie, Centre de Recherche des Cordeliers, Paris, France 4Pa.
Purpose: Targeted drug delivery to the ocular tissues remains a challenge. Biodegradable intraocular implants allow prolonged controlled release of drugs directly into the eye. In this study, we evaluated an anterior suprachoroidal polyurethane implant containing dexamethasone polyurethane dispersions (DX-PUD) as a drug delivery system in the rat model of endotoxin-induced uveitis (EIU).
View Article and Find Full Text PDFShift Work: A Risk Factor for Central Serous Chorioretinopathy.
Am J Ophthalmol
May 2016
Inserm U1138, Team 17, Université Sorbonne Paris Cité, Université Pierre et Marie Curie, Centre de Recherche des Cordeliers, Paris, France; Department of Ophthalmology University of Lausanne, Jules Gonin Ophthalmic Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland.
Purpose: To investigate if shift work or sleep disturbances are risk factors for central serous chorioretinopathy (CSCR).
Design: Prospective case-control study.
Methods: Forty patients with active CSCR and 40 controls (age- and sex-matched) were prospectively recruited from the Ophthalmology Department of Hôtel Dieu Hospital, Paris, between November 2013 and December 2014.
Targeting iron-mediated retinal degeneration by local delivery of transferrin.
Free Radic Biol Med
December 2015
INSERM, UMRS 1138, team Behar-Cohen, From physiopathology of ocular diseases to clinical development, Centre de Recherche des Cordeliers, Paris, France; Université Pierre et Marie Curie-Paris 6, Centre de Recherche des Cordeliers UMRS 1138, Paris, France; Université René Descartes, Centre de Recherche des Cordeliers UMRS 1138, Paris, France; Jules Gonin Ophthalmic Hospital, Lausanne, Switzerland.
Article Synopsis
- Iron is crucial for eye health but can lead to damage if there's too much, necessitating careful regulation of iron levels in the retina.
- Researchers tested the delivery of transferrin (Tf), a protein that binds iron, in animal models to see if it could help protect against retinal degeneration caused by light exposure.
- Results showed that Tf not only reduced harmful iron levels and oxidative stress but also improved retinal function and structure, indicating its potential as a safe treatment for retinal diseases linked to oxidative damage.
Choroidal mast cells in retinal pathology: a potential target for intervention.
Am J Pathol
August 2015
INSERM UMRS1138, Team 17: Physiopathology of Ocular Diseases: From Physiopathology to Clinical Developments, Paris, France. Electronic address:
Mast cells are important in the initiation of ocular inflammation, but the consequences of mast cell degranulation on ocular pathology remain uncharacterized. We induced mast cell degranulation by local subconjunctival injection of compound 48/80. Initial degranulation of mast cells was observed in the choroid 15 minutes after the injection and increased up to 3 hours after injection.
View Article and Find Full Text PDFSPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Retina
December 2015
*Department of Ophthalmology, Hôtel-Dieu of Paris, Assistance Publique Hôpitaux de Paris, Paris, France, Université Sorbonne Paris Cité; †Inserm U1138, Team 17, Université Sorbonne Paris Cité, Université Pierre et Marie Curie, Centre de Recherche des Cordeliers, Paris, France; ‡Department of Ophthalmology, University of Lausanne, Jules Gonin Ophthalmic Hospital, Fondation Asile des aveugles, Switzerland; §Department of Pharmacy Hôtel-Dieu of Paris, Assistance Publique Hôpitaux de Paris, Université Sorbonne Paris Cité, Paris, France; ¶INSERM, U1138, Team 1, Université René Descartes Sorbonne Paris Cité, Université Pierre et Marie Curie Paris, Centre de Recherche des Cordeliers, Paris, France; and **Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Université Paris Diderot, Paris, France.
Purpose: To evaluate the effect of spironolactone, a mineralocorticoid receptor antagonist, for nonresolving central serous chorioretinopathy.
Methods: This is a prospective, randomized, double-blinded, placebo-controlled crossover study. Sixteen eyes of 16 patients with central serous chorioretinopathy and persistent subretinal fluid (SRF) for at least 3 months were enrolled.
PACHYCHOROID: an inherited condition?
Retina
January 2015
*Hôtel-Dieu de Paris, AP-HP, Université Sorbonne Paris Cité, France; †Inserm UMR 1138, Physiopathology of Retinal Diseases: Therapeutic Innovation, Université Sorbonne Paris Cité, France, Centre de Recherche des Cordeliers, Paris, France; and ‡Department of Ophthalmology, University of Lausanne, Jules Gonin Ophthalmic Hospital, Switzerland.
Purpose: Thick choroid (pachychoroid) is associated with central serous chorioretinopathy (CSC), but whether pachychoroid is inherited is unknown.
Methods: In a prospective observational study, first- or second-degree relatives (16 individuals) of 5 patients with CSC had refraction and visual acuity measurement, fundus examination, nonmydriatic photography, and autofluorescence photography. Eyes were graded using the following criteria: 0: normal fundus and autofluorescence photography, 1: focal retinal pigment epithelium hyperfluorescence and/or hypofluorescence and/or retinal pigment epithelial detachment, 2: CSC or diffuse retinal epitheliopathy.
Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation.
Mol Vis
September 2014
Inserm, U1138, Team 17, Physiopathology of ocular diseases : Threrapeutic innovations, Université René Descartes Sorbonne Paris Cité, Centre de Recherche des Cordeliers, Paris, France ; Department of Ophtahlmology of Lausanne University, Jules Gonin Ophthalmic hospital, Lausanne, Switzerland.
Purpose: To evaluate whether anti-vascular endothelial growth factor (VEGF) neutralizing antibodies injected in the vitreous of rat eyes influence retinal microglia and macrophage activation. To dissociate the effect of anti-VEGF on microglia and macrophages subsequent to its antiangiogenic effect, we chose a model of acute intraocular inflammation.
Methods: Lewis rats were challenged with systemic lipopolysaccharide (LPS) injection and concomitantly received 5 µl of rat anti-VEGF-neutralizing antibody (1.